Navigation Links
Targeting cancer with a triple threat
Date:4/15/2014

CAMBRIDGE, MA -- Delivering chemotherapy drugs in nanoparticle form could help reduce side effects by targeting the drugs directly to the tumors. In recent years, scientists have developed nanoparticles that deliver one or two chemotherapy drugs, but it has been difficult to design particles that can carry any more than that in a precise ratio.

Now MIT chemists have devised a new way to build such nanoparticles, making it much easier to include three or more different drugs. In a paper published in the Journal of the American Chemical Society, the researchers showed that they could load their particles with three drugs commonly used to treat ovarian cancer.

"We think it's the first example of a nanoparticle that carries a precise ratio of three drugs and can release those drugs in response to three distinct triggering mechanisms," says Jeremiah Johnson, an assistant professor of chemistry at MIT and the senior author of the new paper.

Such particles could be designed to carry even more drugs, allowing researchers to develop new treatment regimens that could better kill cancer cells while avoiding the side effects of traditional chemotherapy. In the JACS paper, Johnson and colleagues demonstrated that the triple-threat nanoparticles could kill ovarian cancer cells more effectively than particles carrying only one or two drugs, and they have begun testing the particles against tumors in animals.

Longyan Liao, a postdoc in Johnson's lab, is the paper's lead author.

Putting the pieces together

Johnson's new approach overcomes the inherent limitations of the two methods most often used to produce drug-delivering nanoparticles: encapsulating small drug molecules inside the particles or chemically attaching them to the particle. With both of these techniques, the reactions required to assemble the particles become increasingly difficult with each new drug that is added.

Combining these two a
'/>"/>

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Targeting enforcement where needed most in Africas heart of biodiversity
2. New therapies targeting cancer, Alzheimers goal of UH physicist
3. UTMB collaborates on program targeting potential bioterrorist pathogens Ebola and Marburg
4. Targeting metabolism to develop new prostate cancer treatments
5. Going against the flow: Halting atherosclerosis by targeting micro RNA
6. Targeting evolution: Could this be the next strategy to stop superbugs?
7. Targeting cancers sweet tooth
8. Honey bee gene targeting offers system to understand food-related behavior
9. U of M researchers develop model for better testing, targeting of MPNST
10. Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
11. Signalling pathways meeting targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... (UW) have reported for the first time that mammals can ... retinas. Located in the back of the eye, the retina,s ... to the brain. The findings on retina self-repair in ... of the Proceedings of the National Academy of Sciences ...
... Institute of Technology has invited a longtime University of ... and presenting seminars on its campus. Fazle Hussain, ... Engineering, was the sole recipient of the Gordon and ... for Caltech,s division of engineering and applied sciences. The ...
... University have answered a fundamental question of how important ... function, a finding that could provide a new target ... diseases. In a study published this month in ... show for the first time that the specific movements ...
Cached Biology News:Mammals can be stimulated to regrow damaged inner retina nerve cells 2Mammals can be stimulated to regrow damaged inner retina nerve cells 3Celebrated UH researcher invited to Caltech as distinguished scholar 2Scientists present 'moving' theory behind bacterial decision-making 2
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, ... Signaling molecules, became available for purchase in Australia and New ... that RENU 28 works is, if you think about the ... rate of cellular renewal within your body. If you think ... rate of cellular renewal. What RENU 28 does is it ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... DRRX ) announced today that a New ... submitted to the U.S. Food,and Drug Administration (FDA). ... formulation of oxycodone intended to treat moderate to ... designed to resist,common methods of prescription drug misuse ...
... to advance Merrimack,s robust pipeline of biologics ... targeting autoimmune disease and cancer, CAMBRIDGE, Mass., ... the discovery and development of,novel treatments for autoimmune disease and ... Series F private equity financing., Existing and new investors ...
... Bioheart, Inc.,(Nasdaq: BHRT ) today announced that ... common stock to the Nasdaq Capital Market. The Company,s,common ... to The,Nasdaq Capital Market at the opening of business ... a tier of the Nasdaq Stock Market for,companies with ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Biology Products: